APTX News and Press, Aptinyx Inc. From 07/21/21

APTX stock went into long-term depression following a failed trial in 2019. However, the company has continued progressing its oral NMDA receptor modulator in the same indication, in a subgroup. The company has a decent amount of cash. For further details see: Aptinyx: C...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aptinyx (NASDAQ: APTX ) stock looks really promising right here. Source: Pavel Kapysh / Shutterstock.com The company is focused on one thing – the NMDA receptor. This receptor helps our synapses (the conn...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychia...

Inhibikase Therapeutics (IKT) -24% after prices stock offering at $3Blue Apron Holdings (APRN) -19% after announcing share offering.Alfi (ALF) -14%.Clearside Biomedical (CLSD) -10%.TAL Education (TAL) -10%.TDH Holdings (PETZ) -10%.Unique Fabricating (UFAB) -9%.Roblox (RBLX...

Devonyu/iStock via Getty Images Aptinyx (APTX) says that after a Type C meeting with the FDA held recently it has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder ((PTSD)). The program will consist of two separate studies to ev...

Finalizes design for Phase 2b program, which remains on track to commence in 4Q 2021 Corrects statistical analysis from previous exploratory Phase 2 study — no impact on study conclusions or future clinical development plans Aptinyx Inc. (Nasdaq: APTX), a ...

3 Growth Penny Stocks to Watch Right Now Finding growth penny stocks in 2021 can be challenging. With the rise of assets like Bitcoin, DogeCoin, small-caps and everything in between, this year has already become one for the books. Yesterday on June 10th, we saw the small-name biot...

Gainers: Novan (NOVN) +74%.Urban One (UONE) +39%.Iconix Brand (ICON) +28%.Aptinyx (APTX) +24%.Carver Bancorp (CARV) +22%.Vaxart (VXRT) +21%.Xinyuan Real Estate (XIN) +20%Broadway Financial (BYFC) +18%.Amesite (AMST) +18%.Siebert Financial (SIEB) +16%.Losers: Recon Technolo...

Gainers: Novan (NOVN) +81%, Aptinyx (APTX) +25%, Vaxart (VXRT) +39%, Progenity (PROG) +28%, Chemomab Therapeutics (CMMB) +9%.Losers: Orphazyme (ORPH) -41%, Curis (CRIS) -32%, Aptose Biosciences (APTO) -30%, Galecto (GLTO) -22%,&...